Cancer companies do battle

Article

Zmed, a developer of image-guided radiotherapy equipment, has filed suit against Nomos in Boston federal court, alleging patent infringement by Nomos in its recently released ImageSync software on the company's tumor localization system. Zmed's SonArray,

Zmed, a developer of image-guided radiotherapy equipment, has filed suit against Nomos in Boston federal court, alleging patent infringement by Nomos in its recently released ImageSync software on the company's tumor localization system. Zmed's SonArray, an ultrasound-guided adaptive positioning system, uses stereotactic optical guidance and 3D matching software to align the tumor target to the isocenter of the radiotherapy beam. Nomos contends that its new BAT SXi device, which also uses ultrasound to align the radiation beam, does not infringe the Zmed patent, and Nomos has promised to vigorously defend itself against the litigation. Both companies claim victory in a similar court case involving the two last year.

Recent Videos
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
Related Content
© 2025 MJH Life Sciences

All rights reserved.